Shares of Harmony Biosciences Holdings Inc (HRMY) are down sharply after the company announced a public offering of up to 8 million shares. The offering, driven by selling shareholders, will not increase the company’s outstanding share count but could impact investor sentiment and stock price.
Harmony Biosciences Surpasses $2 Billion in Cumulative Revenue, Highlights Robust Pipeline and Expansion into Rare CNS Therapeutic Areas Plymouth Meeting, […]
UBS initiated coverage on Harmony Biosciences Holdings Inc (HRMY) with a Buy rating and a $56 price target, citing strong growth potential for its narcolepsy drug Wakix and a promising pipeline of CNS assets. The firm expects Wakix to achieve $1.2 billion in peak sales, driven by increased narcolepsy diagnosis and the drug’s unique profile in the polypharmacy market.
